Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Fraction Radiosurgery with Temozolomide for GBM
NCT03291990Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temozolomide in glioblastoma multiforme (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Rate of change of lymphopenia at 10 weeks. Started Oct 2017; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT03291990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291990.